Production of actinium-225 from a (n,p) reaction: Feasibility and pre-design studies
Author:
Abolaban Fouad A.1ORCID, Banoqitah Essam M.1, Taha Eslam M.2, Alhawsawi Abdulsalam M.2, Djouider Fathi A.1, Nisbet Andrew3
Affiliation:
1. King Abdulaziz University , Faculty of Engineering, Department of Nuclear Engineering , , Jeddah 21589 , Saudi Arabia 2. King Abdulaziz University , Faculty of Engineering, Department of Nuclear Engineering , , Jeddah 21589 , Saudi Arabia and King Abdulaziz University , Center for Training & Radiation Prevention , , Jeddah 21589 , Saudi Arabia 3. University College London , Department of Medical Physics & Biomedical Engineering, Malet Place Engineering Building , London , UK
Abstract
Abstract
Actinium-225 is used in nuclear medicine for the treatment of malignant tumours. It can be applied to produce Bi-213 in a reusable generator or can be used alone as an agent for radiation therapy, in particular for targeted alpha therapy. However, the availability of Ac-225 for worldwide use, particularly in low- and middle-income countries, is limited. We present a feasibility study employing GATE, an open-source Monte Carlo simulation toolkit, on the production of Ac-225 from a neutron generator. This work suggests that a design consisting of three concentric cylinders, the innermost a Cf-252 neutron source, the middle nickel cylinder acting as a proton-producing target and the outer cylinder a RaCl2 target may provide a feasible design outline for an Ac-225 generator.
Publisher
Walter de Gruyter GmbH
Subject
Waste Management and Disposal,Condensed Matter Physics,Safety, Risk, Reliability and Quality,Instrumentation,Nuclear Energy and Engineering,Nuclear and High Energy Physics
Reference31 articles.
1. Villers, A., & Grosclaude, P. (2008). Épidémiologie du cancer de la prostate. Med. Nucl., 32(1), 2–4. DOI: 10.1016/j.mednuc.2007.11.003. 2. Global Cancer Observatory. (2019). Prostate 2018. Available from https://gco.iarc.fr/today/data/fact-sheets/cancers/27-Prostate-fact-sheet.pdf. 3. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin., 68(6), 394–424. DOI: 10.3322/caac.21492. 4. Davison, B. J., Gleave, M. E., Goldenberg, S. L., Degner, L. F., Hoffart, D., & Berkowitz, J. (2002). Assessing information and decision preferences of men with prostate cancer and their partners. Cancer Nurs., 25(1), 42–49. 5. Hofman, M. S., Violet, J., Hicks, R. J., Ferdinandus, J., Thang, S. P., Akhurst, T., Iravani, A., Kong, G., Kumar, A. R., Murphy, D. G., Eu, P., Jackson, P., Scalzo, M., Williams, S. G., & Sandhu, S. (2018). [177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol., 19(6), 825–833. DOI: 10.1016/S1470-2045(18)30198-0.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|